Navigation Links
iBio, Inc. Receives Approval from NYSE MKT of Compliance Plan
Date:2/13/2013

NEWARK, Del., Feb. 13, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that it has been notified by the NYSE MKT (the "Exchange") Staff that the Exchange has accepted the Company's plan of compliance which was submitted on December 21, 2012.  The plan submitted in December 2012 was in response to the Staff's notice that the Company was not in compliance with the Exchange's continued listing requirement set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide.  This rule requires a listed company to have stockholders' equity of at least  $6,000,000 if it has experienced net losses in its five most recent fiscal years.  In connection with accepting the Company's compliance plan, the Exchange has granted the Company an extension until October 14, 2013 to regain compliance with the $6,000,000 stockholders' equity requirement.

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

During the extension period, the Company will be subject to periodic review by the Staff of the Exchange.  The failure by the Company to make progress consistent with the accepted plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

In addition to the foregoing, the Company expects to receive notice from the Exchange that it does not satisfy the $4,000,000 stockholders' equity requirement set forth in  Section 1003(a)(ii) of the NYSE MKT Company Guide following the filing of its Form 10-Q for the quarterly period ended December 31, 2012, since it experienced net losses in three of its most recent four fiscal years.  The Company anticipated this when it submitted its compliance plan and designed the compliance plan, which has now been accepted, to address its non-compliance with both the $6,000,000 and $4,000,000 stockholders' equity requirements.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more. Additional benefits may include: surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products by increasing potency and lengthening duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements 

Various statements in this release concerning iBio's future expectations, plans and prospects, including without limitation, iBio's ability to regain compliance with the continued listing standards on a timely basis constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, without limitation, iBio's failure to make progress consistent with the plan approved by the Exchange or iBio's failure to meet other criteria necessary for continued listed on the Exchange, as well as those risks more fully discussed in the "Risk Factors" section of the documents filed by the Company with the Securities and Exchange Commission.  In addition, any forward-looking statements represent iBio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.  iBio does not assume any obligation to update any forward-looking statements.

Contacts

iBio, Inc.

Corporate:
Robert Erwin ,
President         
302-355-2335
rerwin@ibioinc.com

Investors:
Doug Beck ,
Chief Financial Officer
302-355-0923
dbeck@ibioinc.com

 


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
2. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
3. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
4. Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger Sequencing Platform and HLA Typing Kits
5. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
6. Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award
7. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
8. Virtual Ports Receives Patent Approvals in the United States and Japan
9. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
10. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
11. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... -- Today Stock-Callers.com have issued research reports on ... (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: ... These companies are part of the Healthcare sector, which gave ... rd , 2017, with the NYSE Health Care Index declining ... in the S&P 500 were down about 0.4% as a ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... provide care from the clinic, which opened March 22, 2017. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the ... create a communications platform that positions them as the go-to thought leader in ... their online publication as an always-on, always-fresh news, views and advocacy engine, called ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian ... Bible teacher residing in North Carolina with his wife, Anna Marie. He and his ... six grandchildren. David is also the author of “Shadow and Substance.” , “Love, the ...
(Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
Breaking Medicine News(10 mins):